INPP5E

INPP5E provides the code for inositol polyphosphate-5-phosphatase E, an enzyme that shapes the chemical makeup of cell membranes and controls signals passed through the cell. This enzyme is concentrated at the primary cilium, a small projection that acts like an antenna on many cell types. In the retina, photoreceptors (the rod and cone cells that capture light) have a specialized version of this antenna, and INPP5E helps them build and renew their light-sensing outer segments. Because so many organs rely on healthy cilia, conditions caused by INPP5E belong to a family of diseases called ciliopathies. The best-known ciliopathy (definition: A disease caused by a problem with cilia — tiny hair-like structures on cells, including the light-sensing cells in the retina, that the cell needs to work properly.) linked to this gene is Joubert syndrome, a disorder marked by a distinctive midbrain-and-hindbrain malformation that can be accompanied by retinal, kidney, and liver involvement.

Retinal degeneration is one of the recognized features of INPP5E-related disease, and it can appear with or without the other features of Joubert syndrome. In people described in the available studies, the eye disease has ranged from a severe, very early form resembling Leber congenital amaurosis to a milder, later-onset rod-cone dystrophy. A rod-cone pattern typically affects rod cells first, which can mean difficulty seeing in dim light and gradual narrowing of side vision before central vision is affected. In one woman followed over six years, imaging showed a steady shrinking of the healthy photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) band and a decline in cone electrical responses, while her central visual acuity stayed stable during that window. Among people with Joubert syndrome, retinal degeneration occurs in roughly one-third of patients, and the retinal disease linked specifically to INPP5E has generally been reported as milder than that seen with some other Joubert genes. Because presentation varies so widely, a specific INPP5E result does not by itself predict how severe or how fast any one person's vision changes will be.

INPP5E is a well-established cause of Joubert syndrome, and it has been identified in multiple independent patient cohorts. More recently, researchers have confirmed that harmful changes in both copies of the gene can also cause inherited retinal degeneration without the full set of Joubert features, described across several families. The gene has also been linked to MORM syndrome, a rare condition that combines intellectual disability, obesity, retinal dystrophy, and genital underdevelopment. A particular INPP5E change appears to be a recurring, region-specific (founder) cause of ciliopathy (definition: A disease caused by a problem with cilia — tiny hair-like structures on cells, including the light-sensing cells in the retina, that the cell needs to work properly.) in Northern Pakistan. Laboratory studies in human retinal organoids and in mice have shown that losing INPP5E disrupts the building and upkeep of photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) outer segments, helping explain why the retina is vulnerable.

Researchers have not found a clear link between which specific INPP5E changes a person carries and how severe their disease will be, and they suspect other modifying genes play a role. Why the same gene causes eye-only disease in some people and full Joubert syndrome in others is not yet understood. A preprint reported INPP5E among ciliopathy (definition: A disease caused by a problem with cilia — tiny hair-like structures on cells, including the light-sensing cells in the retina, that the cell needs to work properly.) genes found in adults with a kidney condition called focal segmental glomerulosclerosis in a highly consanguineous cohort, but this finding has not yet been peer-reviewed and needs confirmation. An unusual single case of one-sided retinitis pigmentosa with a small eye also mentioned an INPP5E variant alongside other changes, but such isolated reports do not establish a new disease pattern.

No therapy that specifically corrects or compensates for INPP5E has been approved, and the studies in the supplied evidence are natural-history and laboratory research rather than treatments. In human stem-cell-derived retinal organoids, removing INPP5E disrupted the formation of photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) outer segment membranes, and similar defects were seen in mouse models — work that helps define what a future treatment would need to fix. A six-year study of one patient identified measurable imaging and electrical markers of progression, which the authors suggest could serve as endpoints in future clinical trials.

• How loss of INPP5E harms photoreceptors

  Laboratory research in cultured human retinal organoids.

  What was found:

  Losing INPP5E altered early retinal development and disrupted the outer segment membranes of both rod and cone photoreceptors, with mislocalized rhodopsin.

  Why it matters:

  It clarifies the biological role of the gene in the retina and provides a human model for testing future therapies.

  Limitation: This is a cellular model, not a treatment, and organoids do not fully reproduce a living retina.

• INPP5E can cause retinal disease without full Joubert syndrome

  Observational human case series with protein modeling.

  What was found:

  The study confirmed that INPP5E variants can cause inherited retinal degeneration on their own, and found no clear link between specific variants and disease severity.

  Why it matters:

  It establishes eye-predominant INPP5E disease as a real entity, which helps explain a result that does not come with obvious syndrome features.

  Limitation: The number of families is small, severity could not be predicted from the variants, and genetic modifiers are suspected but unproven.

• A spectrum from Leber congenital amaurosis to milder rod-cone dystrophy

  Human clinical study reported as a preprint.

  What was found:

  Four probands had severe early-onset disease resembling Leber congenital amaurosis and eight had a milder, later-onset rod-cone dystrophy; two had mild ciliopathy signs that resolved in childhood.

  Why it matters:

  It shows how widely the same gene's retinal effects can vary from person to person.

  Limitation: As a preprint it has not completed peer review, and no consistent genotype-phenotype pattern emerged.

• Six-year natural history and possible trial markers

  Longitudinal single-case observational study.

  What was found:

  The healthy photoreceptor band narrowed steadily and cone electrical responses declined, while central visual acuity remained stable over the period.

  Why it matters:

  It identifies measurable markers that could be used to track disease and to judge future treatments.

  Limitation: Findings from one person may not represent the full range of INPP5E disease.

• Eye findings in Joubert syndrome and how INPP5E compares

  Prospective observational cohort.

  What was found:

  Retinal degeneration was present in a minority of examined patients, and INPP5E-associated retinal disease was generally milder than that caused by some other Joubert genes such as CEP290 and AHI1.

  Why it matters:

  It gives context for what retinal involvement can look like within Joubert syndrome and where INPP5E tends to fall.

  Limitation: The INPP5E subgroup within the cohort is small, so gene-specific conclusions are limited.

Because INPP5E disease is autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.), an affected person has changes in both gene copies, and each parent typically carries one change without being affected. When INPP5E causes Joubert or MORM syndrome, families may need to watch for features beyond vision, including developmental delay and low muscle tone, kidney and liver involvement, extra fingers or toes, and, in MORM syndrome, obesity and metabolic problems. Retinal degeneration in this condition can begin in infancy or childhood, so early and regular eye evaluation can be important for a child's development and support planning.

• Does my genetic result point to eye-only disease, or should I be evaluated for the brain, kidney, and liver features associated with this gene?
• Given my specific variants, what type of retinal degeneration pattern is most consistent with my exam and testing?
• How often should my retinal structure and function be monitored to track any change over time?
• Are there systemic tests, such as kidney or liver assessment, that you would recommend now or in the future?
• What does an autosomal recessive result mean for my children, siblings, and other relatives?
• Would genetic counseling or family testing be useful for my family members?

Because INPP5E can be associated with features beyond the eye, it is worth discussing with a clinician whether evaluation of the brain, kidneys, and liver is appropriate in your situation. Confirming the specific variants and their inheritance with a genetic counselor can clarify what the result means for you and your relatives. If you are interested in research studies, RP Hope's Clinical Trials Finder can help you screen for options with INPP5E preselected.